bluuebunny/crossref_metadata_2025_split huggingface dataset:
Cancer Chemopreventive Activity of Lupane‐ and Oleanane‐Type Triterpenoids from the Cones of Liquidamber styraciflua
Authors: Fukuda Yuko , Sakai Kuniyoshi , Matsunaga Shunyo , Tokuda Harukuni , Tanaka Reiko 
Published: March 2005

AbstractIn a search for cancer chemopreventive agents from natural sources, four lupane‐type and seven oleanane‐type triterpenoids, and ten synthetic analogs were screened as potential anti‐tumor promoters by using the in vitro short‐term 12‐O‐tetradecanoylphorbol‐13‐acetate (TPA)‐induced Epstein–Barr virus early antigen (EBV‐EA) activation assay. Among them, 25‐acetoxy‐3α‐hydroxyolean‐12‐en‐28‐oic acid (1) and 3β,25‐epoxy‐3α‐hydroxylup‐20(29)‐en‐28‐oic acid (2) were examined for anti‐tumor promoting activity in a two‐stage carcinogenesis assay on mouse skin with 7,12‐dimethylbenz[a]anthracene (DMBA) and TPA as promoter. 25‐Acetoxy‐3α‐hydroxyolean‐12‐en‐28‐oic acid (1) and 3β,25‐epoxy‐3α‐hydroxylup‐20(29)‐en‐28‐oic acid (2) showed moderate inhibitory activities.
Urea and Thiourea Derivatives as Low Molecular‐Mass Organogelators
Authors: George Mathew , Tan Grace , John Vijay T. , Weiss Richard G. 
Published: March 2005

AbstractThe properties of a series of organogels consisting of a urea or thiourea derivative with one or two n‐alkyl substitutuents at the nitrogen atoms (a low molecular‐mass organogelator (LMOG)) and an organic liquid are described. They include N,N′‐dimethylurea, the LMOG of lowest molecular mass (MW 88) we are aware of. The efficiencies of the LMOGs, based the diversity of liquids gelated, the minimum amount required for gelation of a liquid at room temperature, and the temporal and thermal stabilities of the gels formed, have been investigated as a function of the number, length, and substitution pattern of their n‐alkyl chains. The gels are thermally reversible and require generally very low concentrations (<2 wt %) of an LMOG. Some of the LMOGs with shorter chains are more efficient than their longer chained analogues. The structural and thermodynamic properties of the gels have been examined by IR, DSC, and X‐ray diffraction techniques. Polarizing optical microscopic analyses of the gels show that the nature of gelator aggregates depends mainly on the alkyl chain length. Changes in the aggregation ability have been examined systematically by perturbing the molecular structure.
Oxygen Atom Transfer in Models for Molybdenum Enzymes: Isolation and Structural, Spectroscopic, and Computational Studies of Intermediates in Oxygen Atom Transfer from Molybdenum(VI) to Phosphorus(III)
Authors: Millar Andrew J. , Doonan Christian J. , Smith Paul D. , Nemykin Victor N. , Basu Partha , Young Charles G. 
Published: March 2005

AbstractIntermediates in the oxygen atom transfer from MoVI to PIII, [TpiPrMoOX(OPR3)] (TpiPr=hydrotris(3‐isopropylpyrazol‐1‐yl)borate; X=Cl−, phenolates, thiolates), have been isolated from the reactions of [TpiPrMoO2X] with phosphines (PEt3, PMePh2, PPh3). The green, diamagnetic oxomolybdenum(IV) complexes possess local C1 symmetry (by NMR spectroscopy) and exhibit IR bands assigned to ν(MoO) (approximately 950 cm−1) and ν(PO) (1140–1083 cm−1) vibrations. The X‐ray crystal structures of [TpiPrMoOX(OPEt3)] (X=OC6H4‐2‐sBu, SnBu), [TpiPrMoO(OPh)(OPMePh2)], and [TpiPrMoOCl(OPPh3)] have been determined. The monomeric complexes exhibit distorted octahedral geometries, with coordination spheres composed of tridentate fac‐TpiPr and mutually cis monodentate terminal oxo, phosphoryl (phosphine oxide), and monoanionic X ligands. The electronic structures and stabilities of the complexes have been probed by computational methods, with the three‐dimensional energy surfaces confirming the existence of a low‐energy steric pocket that restricts the conformational freedom of the phosphoryl ligand and inhibits complete oxygen atom transfer. The reactivity of the complexes is also briefly described.
Diphenylamino End‐Capped Oligofluorenes with Enhanced Functional Properties for Blue Light Emission: Synthesis and Structure–Property Relationships
Authors: Li Zhong Hui , Wong Man Shing , Tao Ye , Lu Jianping 
Published: March 2005

AbstractA novel series of monodisperse asymmetrically and symmetrically substituted diphenylamino end‐capped oligofluorenes, OF(2)‐NPhR, R = H or An (An = 9‐anthryl) and OF(n)‐NPh, n = 2–4, has been synthesized by a convergent approach using palladium‐catalyzed Suzuki cross‐coupling. End‐capping of oligofluorenes with diphenylamino group(s) has been shown to offer advantages in terms of lowering their first ionization potentials, enhancing thermal stability, and inducing good amorphous morphological stability. By tuning the number of diphenylamino end‐caps and the chain length, the optimal conjugated length for optical and luminescence properties has been determined. Of all the hitherto reported oligofluorenes capable of serving as non‐doped blue emitters, OF(3)‐NPh, with an optimal conjugated length, exhibits some of the best hole‐transport and blue‐emitting properties. A maximum luminance of 7500 cd m−2 and a luminance efficiency up to 1.8 cd A−1 have been achieved.
Significant Enhancement of the Stille Reaction with a New Combination of Reagents—Copper(I) Iodide with Cesium Fluoride
Authors: Mee Simon P. H. , Lee Victor , Baldwin Jack E. 
Published: March 2005

AbstractThe combination of copper(I) iodide and cesium fluoride significantly enhances the Stille reaction. After extensive optimisation, a variety of electronically unfavourable and sterically hindered substrates were coupled in very high yields under mild conditions.
Exploring SmBr2‐, SmI2‐, and YbI2‐Mediated Reactions Assisted by Microwave Irradiation
Authors: Dahlén Anders , Prasad Edamana , Flowers Robert A. , Hilmersson Göran 
Published: March 2005

AbstractThe use of microwave heating in lanthanide(II) halide (LnX2=SmBr2, SmI2, and YbI2) mediated reduction and coupling reactions has been investigated for a variety of functional groups including α,β‐unsaturated esters, aldehydes, ketones, imines, and alkyl halides. Good to quantitative transformations were obtained within a few minutes without the addition of any co‐solvents, such as hexamethyl phosphoramide (HMPA). The redox potential of YbI2 in tetrahydrofuran (THF) has been determined as −1.02±0.05 V (versus Ag/AgNO3) by cyclic voltammetry. A large selectivity difference in various reactions was observed depending on the redox potential of the LnX2 reagent. The more powerful reductant, SmBr2, afforded mainly pinacol‐coupling products of ketones whereas the weaker reductant YbI2 afforded mainly reduction products. The results indicate that the reducing power of LnX2 has a large impact on not only the pinacol coupling/reduction product ratio of ketones but also on other substrates in which there are competing coupling and reduction reactions. The use of in situ generated LnX2 has also been explored and proven useful in many of these reactions.
[Nd6(μ6‐O)(μ3‐OH)8 (H2O)24]I8(H2O)12 — The First Basic Rare Earth Iodide with an Oxygen‐Centred M6X8‐Cluster Core.
Authors: Mudring Anja‐Verena 
Published: March 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Synthesis, Crystal Structure and Electronic Structure of Modulated Pd7‐δSnTe2.
Authors: Savilov S. V. , Kuznetsov A. N. , Popovkin B. A. , Khrustalev V. N. , Simon P. , Getzschmann J. , Doert Th. , Ruck M. 
Published: March 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Reduced Lanthanum Halides with Ge as Interstitials: La2I2Ge, La2I2Ge2, La3Cl2Ge3, La3Br2Ge3, La3I3Ge, La6I5Ge3 and La7+xI12Ge.
Authors: Mattausch Hansjuergen , Zheng Chong , Ryazanov Mikhail , Simon Arndt 
Published: March 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Tb3O2Cl[SeO3]2 and Tb5O4Cl3[SeO3]2: Oxide Chloride Oxoselenates(IV) of Trivalent Terbium with “Lone‐Pair” Channel or Layer Structures.
Authors: Wontcheu Joseph , Schleid Thomas 
Published: March 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Double Mitsunobu Reactions of cis‐Cycloalk‐2‐ene‐1,4‐diols and 3,4‐Epoxycycloalkenes: Rearrangements of Allylic Diazides.
Authors: Goeksu Sueleyman , Ozalp Cagri , Secen Hasan , Suetbeyaz Yasar , Saripinar Emin 
Published: March 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Meerwein—Ponndorf—Verley Alkynylation of Aldehydes: Essential Modification of Aluminum Alkoxides for Rate Acceleration and Asymmetric Synthesis.
Authors: Ooi Takashi , Miura Tomoya , Ohmatsu Kohsuke , Saito Akira , Maruoka Keiji 
Published: March 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Highly Efficient Epoxidation Method of Olefins with Hydrogen Peroxide as Terminal Oxidant, Bicarbonate as a Cocatalyst and Oxodiperoxo Molybdenum(VI) Complex as Catalyst.
Authors: Gharah Narottam , Chakraborty Santu , Mukherjee Alok K. , Bhattacharyya Ramgopal 
Published: March 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Alumina Supported Potassium Permanganate: An Efficient Reagent for Chemoselective Dehydrogenation of 2‐Imidazolines under Mild Conditions.
Authors: Abdollahi‐Alibeik Mohammad , Mohammadpoor‐Baltork Iraj , Zolfigol Mohammad Ali 
Published: March 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Reactions of Zinc Enolates Derived from 1‐Aryl‐2,2‐di‐bromoalkanones with 2‐Acyl‐3H‐benzo[f]chromen‐3‐ones, 6‐Bromo‐2‐oxochromene‐3‐carboxamides, and 3‐Oxo‐3H‐benzo[f]chromene‐2‐carboxamides.
Authors: Shchepin V. V. , Kalyuzhnyi M. M. , Silaichev P. S. , Russkikh N. Yu. , Shchepin R. V. , Ezhikova M. A. , Kodess M. I. 
Published: March 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
A Concise Synthesis of 2,4‐Disubstituted Pyridines: A Convenient Synthesis of 2‐Bromo‐4‐iodopyridine via Halogen Dance and Its Successive One‐Pot Disubstitutions
Authors: Duan Xin‐Fang , Li Xiang‐Hong , Li Fu‐You , Huang Chun‐Hui 
Published: March 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Fused Polycyclic Nitrogen‐Containing Heterocycles. Part 9. Synthesis and Molecular Structure of Methyl 3‐(2‐R‐5‐Phenylthiazol‐4‐yl)‐7‐phenyl‐7H‐[1,2,4]triazolo[3,4‐b] [1,3,4]thiadiazine‐6‐carboxylates.
Authors: Mamedov V. A. , Mustakimova L. V. , Gubaidullin A. T. , Litvinov I. A. , Levin Ya. A. 
Published: March 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Terpenoids and Related Compounds. Part 36. Eupacannol, a Pentacyclic Triterpene of a New Skeletal Type, and Other Chemical Constituents from Eupatorium cannabinum.
Authors: Talapatra Sunil Kumar , Bhar Durga Sankar , Chakraborti Ramaprasad , Talapatra Beni 
Published: March 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Synthesis of a Fluorescent Sulfatide for the Study of CD1 Antigen Binding Properties.
Authors: Franchini Laura , Compostella Federica , Donda Alena , Mori Lucia , Colombo Diego , De Libero Gennaro , Matto Pamela , Ronchetti Fiamma , Panza Luigi 
Published: March 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
A New Synthesis Analogue of Thymidine, 7‐(3‐Bromo‐phenoxy)‐thymidine, Inhibits the Proliferation of Tumor Cells.
Authors: Kim Kyung Noo , Lee Jiyong , Kim Dong Hoon , Yoo Jong‐Shin , Kwon Ho Jeong 
Published: March 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Structure—Activity Relationship Study on 13‐Deoxytedanolide, a Highly Antitumor Macrolide from the Marine Sponge Mycale adhaerens.
Authors: Nishimura Shinichi , Matsunaga Shigeki , Yoshida Satoru , Nakao Yoichi , Hirota Hiroshi , Fusetani Nobuhiro 
Published: March 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Novel Diarylsulfonylurea Derivatives as Potent Antimitotic Agents.
Authors: Kim Semi , Park Ji Hyun , Koo Sun‐Young , Kim Jung In , Kim Min‐Hyeung , Kim Ji Eun , Jo Kiwon , Choi Hwan Geun , Lee Sung Bae , Jung Sang‐Hun 
Published: March 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Metallo‐Silanols and Metallo‐Siloxanes. Part 27. Synthesis and Reactivity of Silicon Transition Metal Complexes. Part 55. Metallo‐Silanols — Precursors for the Generation of Novel Metallo‐Siloxanes and Metallo‐Heterosiloxanes
Authors: Hofmann Marco , Voegler Matthias , Schumacher Dirk , Malisch Wolfgang 
Published: March 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Efficient, Ecologically Benign, Aerobic Oxidation of Alcohols
Authors: Marko Istvan E. , Giles Paul R. , Tsukazaki Masao , Chelle‐Regnaut Isabelle , Gautier Arnaud , Dumeunier Raphael , Philippart Freddi , Doda Kanae , Mutonkole Jean‐Luc , Brown Stephen M. , et al. et al. 
Published: March 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Survey of Briarane‐Related Diterpenoids. Part 2
Authors: Sung Ping‐Jyun , Chang Pi‐Chen , Fang Lee‐Shing , Sheu Jyh‐Horng , Chen Wei‐Chen , Chen Yu‐Pei , Lin Mei‐Ru 
Published: March 2005

AbstractFor Abstract see ChemInform Abstract in Full Text.
Chemosensitization by STI571 targeting the platelet‐derived growth factor/platelet‐derived growth factor receptor‐signaling pathway in the tumor progression and angiogenesis of gastric carcinoma
Authors: Kim Ryungsa , Emi Manabu , Arihiro Koji , Tanabe Kazuaki , Uchida Yoko , Toge Tetsuya 
Published: March 2005

AbstractBACKGROUNDAutocrine and paracrine growth mediated by the platelet‐derived growth factor (PDGF)/PDGF receptor (PDGFR)‐signaling pathway plays an important role in the progression of solid tumors. The authors assessed the effect of STI571 on the tumor growth of gastric carcinoma in combination with 5‐fluorouracil (5‐FU) or paclitaxel targeting the PDGF/PDGFR‐signaling pathway.METHODSIn MKN‐45 gastric carcinoma cells, the cytotoxic effect was evaluated by 3‐(4,5 dimethiazol‐2‐yl)‐2,5‐diphenyl tetrazolium bromide assay, and the in vivo antitumor effect was evaluated in a nude mouse xenograft. Both STI571 and an antitumor drug were administered intraperitoneally. Gene expression was assessed by Western blot analysis and immunohistochemical staining. Apoptotic cell death was evaluated by the terminal deoxyuridine triphosphate‐biotin nick‐end labeling assay, and tumor angiogenesis was evaluated by microvessel density analysis.RESULTSTreatment with STI571 alone was not effective in vitro, as assessed by a 50% inhibitory concentration value of 24.3 μM. Combination treatment with STI571 and 5‐FU or paclitaxel enhanced the cytotoxic effect somewhat when the concentration of STI571 was increased to 10 μM. Combination treatment with STI571 and 5‐FU or paclitaxel enhanced the antitumor effect of the antitumor drug significantly in vivo. The enhanced antitumor effect was associated with increased apoptotic cell death and inhibition of tumor angiogenesis. Treatment with STI571 down‐regulated the expression of PDGF‐BB and PDGFR‐β in tumor cells and decreased the production of phosphorylated PDGFR‐β and phosphorylated Akt. Furthermore, treatment with STI571 inhibited the expression of PDGFR‐β in stromal cells.CONCLUSIONSSTI571 was an effective chemosensitizer of antitumor drugs, such as 5‐FU and paclitaxel for gastric carcinoma, targeting the PDGF/PDGFR‐signaling pathway of tumor cells and stromal cells in disease progression and angiogenesis. Cancer 2005. © 2005 American Cancer Society.
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib
Authors: Marin David , Kaeda Jaspal S. , Andreasson Catharina , Saunders Sue M. , Bua Marco , Olavarria Eduardo , Goldman John M. , Apperley Jane F. 
Published: March 2005

AbstractBACKGROUNDA Phase I/II study was designed to show whether the addition of semisynthetic homoharringtonine (sHHT) would reduce the level of residual disease in patients with Ph‐positive chronic myeloid leukemia who appeared to have achieved a suboptimal response to imatinib alone.METHODSPatients with CML who had achieved ≥ 35% Ph‐negativity on imatinib were included. All patients had been treated with imatinib at ≥ 400 mg/day for at least 2 years and had achieved a plateau in BCR‐ABL transcripts defined by measuring BCR‐ABL transcripts on at least 4 occasions over a minimum period of 1 year with the latest value not lower than the previous minimum value. Initially sHHT was given subcutaneously at a dose of 1.25 mg/m2 twice daily for 1 day. Courses were repeated every 28 days. The dosage of sHHT was escalated by adding one day of treatment every two days. Efficacy was assessed by serial monitoring of blood levels of BCR‐ABL transcripts.RESULTSOf 10 evaluable patients, 7 had an appreciable decline in BCR‐ABL transcript levels; in 5 cases the reduction was greater than 1 log. Asthenia (n = 10) and cytopenias (n = 3) were prominent side‐effects, but the drug was generally well tolerated. Mutations in the P‐loop of the BCR‐ABL kinase domain were found in 2 of the patients who responded to the addition of sHHT.CONCLUSIONSThe addition of sHHT should be considered for patients on imatinib who fail to obtain low levels of minimal residual disease. Cancer 2005. © 2005 American Cancer Society.
Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma
Authors: Gong Yun , Booser Daniel J. , Sneige Nour 
Published: March 2005

AbstractBACKGROUNDAccurate assessment of HER‐2 status is necessary prior to anti‐HER‐2 antibody (trastuzumab) therapy for metastatic breast carcinoma. However, controversy exists regarding whether to assess HER‐2 status in the primary tumor or in metastatic lesions. It is also unclear whether HER‐2 status can change during disease progression or after chemotherapy.METHODSBreast carcinoma samples from 60 women with known HER‐2 status in both primary tumors and paired metastases (locoregional disease, n = 43 patients; distant disease, n = 17 patients) were reviewed retrospectively. Thirty‐two patients underwent chemotherapy before their metastatic lesions were sampled, including 18 patients who received neoadjuvant chemotherapy and 14 patients who received adjuvant chemotherapy. The HER‐2 gene was examined by fluorescence in situ hybridization either in paraffin‐embedded tissue samples (48 primary tumors and 9 metastatic tumors) or in fine‐needle aspirates (12 primary tumors and 51 metastatic tumors). HER‐2 gene amplification was defined as a HER‐2:chromosome 17 signal ratio ≥ 2.0.RESULTSThe HER‐2 status of primary and metastatic tumors agreed in 58 of 60 patients (97%), including 18 (30%) amplified tumors and 40 (67%) nonamplified tumors. A discrepancy in HER‐2 status was observed in specimens from two patients in which HER‐2 amplification was detected in the primary tumor but not the metastatic tumors. In one patient, three foci of tumor nodules were found in the same breast; the HER‐2 status was assessed in only one of them, which showed amplification; however, HER‐2 amplification was not detected in the axillary lymph node metastasis. In another patient, the HER‐2 gene was amplified in the primary tumor but not in the liver metastasis. No metastases showed HER‐2 amplification without amplification in the primary tumor. Locoregional and distant metastases demonstrated similar concordance rates with their corresponding primary tumors (98% and 94%, respectively). Complete concordance of HER‐2 status was found between primary tumors prior to chemotherapy and metastases that were sampled after chemotherapy.CONCLUSIONSThe HER‐2 status in breast carcinoma generally was stable during metastasis, whether to locoregional or distant sites. Chemotherapy did not modify the HER‐2 status in metastatic lesions. Therefore, HER‐2 amplification can be evaluated reliably in material from either primary or metastatic tumors in most patients. Further study with larger series is warranted to elucidate the significance of discordant results. Cancer 2005. © 2005 American Cancer Society.
Evaluating high‐performance computers
Authors: Vetter Jeffrey S. , de Supinski Bronis R. , Kissel Lynn , May John , Vaidya Sheila 
Published: March 2005

AbstractComparisons of high‐performance computers based on their peak floating point performance are common but seldom useful when comparing performance on real workloads. Factors that influence sustained performance extend beyond a system's floating‐point units, and real applications exercise machines in complex and diverse ways. Even when it is possible to compare systems based on their performance, other considerations affect which machine is best for a given organization. These include the cost, the facilities requirements (power, floorspace, etc.), the programming model, the existing code base, and so on. This paper describes some of the important measures for evaluating high‐performance computers. We present data for many of these metrics based on our experience at Lawrence Livermore National Laboratory (LLNL), and we compare them with published information on the Earth Simulator. We argue that evaluating systems involves far more than comparing benchmarks and acquisition costs. We show that evaluating systems often involves complex choices among a variety of factors that influence the value of a supercomputer to an organization, and that the high‐end computing community should view cost/performance comparisons of different architectures with skepticism. Published in 2005 by John Wiley & Sons, Ltd.
Architectural specification for massively parallel computers: an experience and measurement‐based approach
Authors: Brightwell Ron , Camp William , Cole Benjamin , DeBenedictis Erik , Leland Robert , Tomkins James , Maccabe Arthur B. 
Published: March 2005

AbstractIn this paper, we describe the hardware and software architecture of the Red Storm system developed at Sandia National Laboratories. We discuss the evolution of this architecture and provide reasons for the different choices that have been made. We contrast our approach of leveraging high‐volume, mass‐market commodity processors to that taken for the Earth Simulator. We present a comparison of benchmarks and application performance that support our approach. We also project the performance of Red Storm and the Earth Simulator. This projection indicates that the Red Storm architecture is a much more cost‐effective approach to massively parallel computing. Published in 2005 by John Wiley & Sons, Ltd.
T‐cell lymphoblastic leukemia/lymphoma syndrome with eosinophilia and acute myeloid leukemia
Authors: Lamb Lawrence S. , Neuberg Ronnie , Welsh Jeff , Best Robert , Stetler‐Stevenson Maryalice , Sorrell April 
Published: March 2005

AbstractThis case represents an example of an unusual T‐cell lymphoblastic leukemia/lymphoma syndrome associated with eosinophilia and myeloid malignancy in a young boy. This case is one of only five reported “leukemic” variants of the disease and demonstrates the importance of considering this poor prognostic diagnosis in pediatric acute lymphoblastic leukemia. This case also illustrates the importance of an interactive multidisciplinary approach to the laboratory evaluation of a leukemia patient. © 2005 Wiley‐Liss, Inc.